First Private MHAT Vratsa
- Address
- 95 General Leonov str., 3000 Vratsa, Bulgaria
First Private MHAT Vratsa - Inflammatory Bowel Disease Research
First Private MHAT Vratsa is a specialized clinical research center contributing to advanced therapeutic studies in gastroenterology and inflammatory conditions. The center demonstrates particular expertise in evaluating novel combination therapies for challenging digestive disorders, with a focus on improving treatment outcomes for patients with difficult-to-manage conditions.
- Ulcerative colitis treatment optimization and novel biologics
- Combination therapy approaches for inflammatory bowel diseases
- Advanced immunomodulatory treatments and their efficacy assessment
The research center is actively involved in evaluating innovative therapeutic strategies for moderately to severely active ulcerative colitis, including studies examining combination approaches with guselkumab and golimumab. Their work focuses on comparing the effectiveness of dual therapy against monotherapy options, contributing valuable data to the field of inflammatory bowel disease management and helping to establish new treatment paradigms for patients who require more intensive therapeutic interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in First Private MHAT Vratsa
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy, Safety, and Immunogenicity of Intravenous AVT16 Versus Vedolizumab in Adults with Moderate to Severe Active Ulcerative Colitis | Alvotech Swiss AG | Phase III | Not Recruiting | Aug 2025 | Oct 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Golimumab | 1 | Unknown | 2022-11-30 | 2022-11-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.